Jpmorgan Chase & CO Exelixis, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Exelixis, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 4,430,653 shares of EXEL stock, worth $149 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,430,653
Previous 5,048,856 12.24%
Holding current value
$149 Million
Previous $113 Million 1.35%
% of portfolio
0.01%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$21.96 - $27.6 $13.6 Million - $17.1 Million
-618,203 Reduced 12.24%
4,430,653 $115 Million
Q3 2024

Nov 08, 2024
SELL
$21.96 - $27.6 $13.6 Million - $17.1 Million
-618,203 Reduced 12.24%
4,430,653 $115 Million
Q2 2024

Dec 26, 2024
BUY
$20.34 - $23.73 $12.6 Million - $14.7 Million
618,203 Added 13.95%
5,048,856 $113 Million
Q2 2024

Aug 12, 2024
SELL
$20.34 - $23.73 $5.59 Million - $6.53 Million
-275,003 Reduced 5.17%
5,048,856 $113 Million
Q1 2024

Dec 26, 2024
BUY
$20.17 - $23.93 $18 Million - $21.4 Million
893,206 Added 20.16%
5,323,859 $126 Million
Q1 2024

May 10, 2024
SELL
$20.17 - $23.93 $48.8 Million - $57.9 Million
-2,417,730 Reduced 31.23%
5,323,859 $126 Million
Q4 2023

Dec 26, 2024
BUY
$19.25 - $24.13 $63.7 Million - $79.9 Million
3,310,936 Added 74.73%
7,741,589 $186 Million
Q4 2023

Feb 12, 2024
BUY
$19.25 - $24.13 $1.8 Million - $2.25 Million
93,368 Added 1.22%
7,741,589 $186 Million
Q3 2023

Nov 14, 2023
SELL
$19.04 - $22.74 $903,390 - $1.08 Million
-47,447 Reduced 0.62%
7,648,221 $167 Million
Q2 2023

Aug 11, 2023
SELL
$18.17 - $20.48 $1.25 Million - $1.41 Million
-68,779 Reduced 0.89%
7,695,668 $147 Million
Q1 2023

May 18, 2023
BUY
$16.3 - $19.41 $9.08 Million - $10.8 Million
557,058 Added 7.73%
7,764,447 $151 Million
Q1 2023

May 11, 2023
SELL
$16.3 - $19.41 $86.6 Million - $103 Million
-5,312,565 Reduced 42.43%
7,207,389 $140 Million
Q4 2022

Feb 13, 2023
BUY
$14.96 - $17.39 $2.55 Million - $2.96 Million
170,325 Added 1.38%
12,519,954 $201 Million
Q3 2022

Nov 14, 2022
BUY
$15.68 - $22.27 $3.15 Million - $4.47 Million
200,726 Added 1.65%
12,349,629 $194 Million
Q2 2022

Aug 11, 2022
BUY
$17.44 - $23.16 $1.78 Million - $2.37 Million
102,300 Added 0.85%
12,148,903 $253 Million
Q1 2022

May 11, 2022
BUY
$17.03 - $22.67 $1.76 Million - $2.34 Million
103,192 Added 0.86%
12,046,603 $273 Million
Q4 2021

Feb 10, 2022
BUY
$15.84 - $21.88 $8.15 Million - $11.3 Million
514,336 Added 4.5%
11,943,411 $218 Million
Q3 2021

Nov 12, 2021
BUY
$16.3 - $21.14 $186 Million - $242 Million
11,429,075 New
11,429,075 $242 Million

Others Institutions Holding EXEL

# of Institutions
502
Shares Held
243M
Call Options Held
2.54M
Put Options Held
2.29M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.8B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email